Overview

Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Platinum Resistant Urothelial Bladder Cancer

Status:
Completed
Trial end date:
2018-04-01
Target enrollment:
Participant gender:
Summary
Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Platinum Resistant Metastatic Urothelial Cancer
Phase:
Phase 2
Details
Lead Sponsor:
Acerta Pharma BV
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
Acalabrutinib
Pembrolizumab